Aclaris Therapeutics (ACRS) Debt Ratio (2017)

Aclaris Therapeutics (ACRS) recorded quarterly Debt Ratio of 0.0 in Q4 2017.

Aclaris Therapeutics (ACRS) Debt Ratio (2017) Analysis & Trends

Aclaris Therapeutics' Debt Ratio history runs 1 years deep, the most recent figure standing at 0.0 for Q4 2017.

In Q4 2017, Debt Ratio changed N/A year-over-year to 0.0; the TTM figure through Dec 2017 stood at 0.0 (changed N/A YoY), while the FY2017 annual figure was 0.0, changed N/A from the prior year.
Debt Ratio was 0.0 for Q4 2017 at Aclaris Therapeutics.
In the past five years, Debt Ratio ranged from a high of 0.0 in Q4 2017 to a low of 0.0 in Q4 2017.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	0.18
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Aclaris Therapeutics	580.93 Mn	580.93 Mn	1.60 Mn	-

Historic Data

Download Data

Date	Value
Dec 31, 2017	0.00